Background and Purpose: Inherited protein S deficiency has been associated with an increased risk of thromboembolic disease. It is possible that such a coagulopathy could predispose children to the development of strokes by permitting clot formation in response to stimuli that ordinarily would be insufficient to cause thrombus formation.
T hrombosis of the cerebral dural sinuses or veins
in infants and children is most frequently seen in association with dehydration, metabolic acidosis, sepsis, localized central nervous system infection, or cyanotic heart disease. 1 -4 Central thrombosis has also been described in various hypercoagulable states associated with nephrotic syndrome, acute lymphoblastic leukemia, and congenital antithrombin HI deficiency. [5] [6] [7] [8] We report the case of a 4-year-old boy with cerebral venous thrombosis after a trivial head injury; he had none of the previously reported associated conditions. The search for a factor to explain this clinical event led to the suggestion that protein S deficiency may also be associated with childhood superior sagittal sinus thrombosis.
Materials and Methods
Total protein S antigen was measured in an enzymelinked immunosorbent assay (ELISA) using a mixture of two mouse monoclonal antibodies that recognize both the free and bound fractions of protein S. The antibody mixture was bound to wells of a microtiter plate and the plate washed. Dilutions of patient plasma or a normal standard plasma pool were added to the wells and washed. A mixture of two biotinylated mouse monoclonal antibodies to protein S were then added, the plates were washed, and streptavidin-alkaline phos-phatase conjugate (Zymed, San Francisco) was added. The plates were washed, para-nitrophenyl phosphate (Zymed) was added, and optic density was read in an ELISA reader. Free protein S antigen was measured in an identical assay, with the exception that the bound fraction of protein S in samples or the standard plasma pool was first precipitated with polyethylene glycol and the supernatants containing the free fraction of protein S were analyzed. Protein S crossed-immunoelectrophoresis (CIE) was performed by electrophoresis of patient or normal plasma on an agarose-coated plate in one dimension, followed by electrophoresis in the second dimension at 90° to the first into agarose containing polyclonal rabbit anti-protein S antibody. Precipitin arcs representing the free and bound fractions of protein S were then visualized by staining with Coomassie blue.
Case Report A previously well 4-year-old boy was admitted with an acute onset of headache, lethargy, neck stiffness, and vomiting. Two weeks previously he had struck his head on the underside of a table while rising to a standing position; he sustained a small laceration that required three sutures but appeared to have suffered no other injuries. Noncontrast computed tomography of the head revealed hyperdensities of the straight sinus, superior sagittal sinus, and transverse sinuses. The patient was then transferred to our institution for further evaluation. He had no history of thromboembolic events.
Laboratory studies obtained at the time of admission included an erythrocyte sedimentation rate of 25 mm/ hr; hemoglobin, 12.9 g/dL; hematocrit, 40.5%; and white blood count, 4.9X10 4.3 mg/dL. Liver chemistries (including transaminases, alkaline phosphatase, ammonia, and total bilirubin) were all normal. A magnetic resonance imaging study of the patient's head revealed hyperintensity of the straight sinus, transverse sinuses, and superior sagittal sinus. A focal subdural fluid collection was visualized in the interhemispheric fissure posteriorly extending to the level of the tentorium and cephalad to the level of the convexity (Figure 1 ). On the venous phase of four-vessel angiography, the sagittal sinus failed to opacify, but the arterial phase was normal.
Coagulation studies were as follows: prothrombin time, 11.9 seconds (control, 13.3 seconds); partial thromboplastin time, 24.5 seconds (control, 32 seconds); fibrinogen concentration, 212 mg/dL (normal range, 200-400 mg/dL); and fibrin degradation products, <10 jLig/mL. The antithrombin III concentration was 19 mg/dL (normal, 9-15 mg/dL) and the antithrombin III activity 147 units/dL (normal, 80-130 units/dL). Factor VIII was 140% and factor X 86%. The protein C antigen was 142% (normal, 70-130%), and the protein C activity by a clotting assay was 130% (normal, 65-150%). Although total protein S antigen concentration was 52% (normal, 60-150%), the free protein S antigen was 16% (normal, 66-146%) ( Table 1 ). This significant deficiency of free protein S was confirmed by CIE; the bound fraction of protein S was normal, but the free protein S peak was absent. Family studies showed that the propositus' father and multiple members of his father's family had a similar deficiency of free protein S (Table 1) . However, none of these family members had a history of thrombotic events.
Despite treatment with warfarin after diagnosis of the thrombosis, the patient developed papilledema and symptoms of increased intracranial pressure and eventually required placement of a lumboperitoneal shunt. He has remained on anticoagulant therapy with warfarin and has had no further episodes of thrombosis. Two years after the thrombotic event, repeated studies confirmed his protein S deficiency; the total protein S antigen was 21% (range in normal adults taking therapeutic doses of warfarin, 30-78%), and the free protein S antigen was <6% (range in normal adults taking therapeutic doses of warfarin, 19-55%).
Discussion
Cerebral venous thrombosis related to protein S deficiency is rare. 9 ' 12 Other thrombotic events associated with this factor have been reported, 10 including cerebral arterial thrombosis in a 4-month-old infant. 13 Protein S is a vitamin K-dependent plasma protein that functions to inhibit blood clotting by serving as a cofactor for activated protein C.
11 Activated protein C binds to protein S that is attached to the phospholipids of platelet or vascular endothelial surfaces. This protein C-S complex inhibits the clotting cascade by enzymatic inactivation of factors Va and Villa and promotes fibrinolysis by dissociation of tissue plasminogen activator from its inhibitor, plasminogen activator inhibitor. Protein S circulates both in a free form, which is the active protein C cofactor, and in a physiologically inactive form complexed to complement component C4b binding protein. Therefore, it is necessary to estimate the free as well as the total immunoreactive protein S levels to evaluate a suspected hypercoagulable state.
Previous studies have demonstrated a higher lifetime risk of venous thrombosis in individuals with congenital protein S deficiency. 10 Recent case reports also suggest a relation between familial protein S deficiency and arterial thrombosis. 1415 The deficiency of a physiological anticoagulant such as protein S, protein C, or antithrombin III may predispose an individual to thrombogenesis either spontaneously or when a trigger is present. 12 Such a hemostatic imbalance favoring clot formation could predispose an individual to the development of strokes by permitting thrombi to form in response to stimuli that ordinarily would be insufficient to cause thrombus formation. We speculate that in this case, in the setting of free protein S deficiency resulting in the lack of normal physiological inhibition of coagulation, the minor head trauma may have disrupted the endothelial integrity of the cerebral veins sufficiently to allow pathological thrombus formation.
The patient's father and three paternal cousins also had decreased free protein S on CIE and decreased free protein S antigen values. These findings, plus the persistence of free protein S deficiency after resolution of the acute thrombosis, lead us to propose that the patient was affected by inherited free protein S deficiency rather than consumption of protein S by the thrombotic process. Since the determination that the protein S deficiency was inherited placed the patient at lifelong risk for thrombosis, the decision was made to treat the patient indefinitely with warfarin as currently recommended for protein S-deficient patients who have experienced a thrombotic event. 10 Although lifelong anticoagulant therapy is not currently recommended for asymptomatic individuals, the identification of affected family members allows the initiation of preventive measures during known periods of additional thrombotic risk such as major surgery and pregnancy.
This case extends the clinical spectrum of protein S deficiency to include cerebral venous thrombosis in young children. Children in whom cerebral vein thrombosis occurs in the absence of an associated hypercoagulable state should be tested for protein S and other physiological anticoagulant deficiencies. If a deficiency is found or it is unclear whether the deficit is inherited or acquired, family studies should be undertaken. Once identified, prompt specific therapy can be initiated.
